AppliedVR and National Cancer Institute Collaborate on Research Evaluating Virtual Reality for Reducing Anxiety in Primary Brain Tumor Patients During Imaging Services
LOS ANGELES, July 20, 2023 /PRNewswire/ -- AppliedVR, an immersive therapeutics (ITx) pioneer advancing a novel approach to medicine, today announced interim analysis results of a phase 2 clinical trial study performed in collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). The phase 2 clinical trial explored whether virtual reality (VR) could be an intervention for primary brain tumor (PBT) patients who experience distress and anxiety prior to their clinical evaluations. The study is part of an ongoing collaboration agreement between AppliedVR and the NCI and is led by the Neuro-Oncology Branch (NOB), Center for Cancer Research (CCR), NCI. The patient population of the study is comprised of patients who are actively enrolled in NOB's Natural History Study.
- The phase 2 clinical trial explored whether virtual reality (VR) could be an intervention for primary brain tumor (PBT) patients who experience distress and anxiety prior to their clinical evaluations.
- The study is part of an ongoing collaboration agreement between AppliedVR and the NCI and is led by the Neuro-Oncology Branch (NOB), Center for Cancer Research (CCR), NCI.
- The patient population of the study is comprised of patients who are actively enrolled in NOB's Natural History Study .
- In the future, the two organizations may continue to work together to expand and deepen research that evaluates how immersive therapeutics can help serve cancer patients.